Wu Heyan, Fang Xiang, Xia Zhengkun, Gao Chunlin, Peng Yingchao, Li Xiaojie, Zhang Pei, Kuang Qianghuining, Wang Ren, Wang Meiqiu
Department of Pediatrics, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, China.
Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
J Nephrol. 2020 Dec;33(6):1263-1273. doi: 10.1007/s40620-020-00767-4. Epub 2020 Jun 7.
The long-term renal outcome for IgA nephropathy (IgAN) in large cohorts of children remains unclear. IgAN is a progressive disease, to explore novel biomarkers is necessary for predicting the disease activity and progression of IgAN. In addition, there is a hot debate on when to treat with immunosuppression in children. We aimed to confirm the long-term renal survival, find some undetected risk factors and investigate when to treat with immunosuppression can benefit for renal outcome in Chinese children.
1243 Children with IgAN were enrolled and a follow-up of at least 1 year after a biopsy from 2000 to 2017. Long-term renal survival, undetected risk factors and the renal survival of immunosuppressive and non-immunosuppressive therapy were evaluated. The primary endpoint of the study was a combined outcome of either ≥50% reduction in estimated glomerular filtration rate (eGFR) or end-stage renal disease (ESRD) or death.
The median follow-up time were 86.8 months (interquartile range 54.7-140.2 months). The 5-, 10- and 15-year renal survival rates were 95.3%, 90.3% and 84%, respectively. Cox multivariate regression and Kaplan-Meier analysis showed that hypertension, hyperuricemia, high 24 h urine protein (24 h-UP) levels, lower initial eGFR, high urine C3 levels, high retinol-binding protein (RBP) levels, segmental glomerulosclerosis (S) and tubular atrophy and interstitial fibrosis (T) were associated with renal outcome. The statistically significant predictive perfect power for renal outcome was RBP ≥ 0.7µg/ml (AUC = 0.899, sensitivity = 84.00%, specificity = 86.00%), 24 h-UP ≥ 1 g/24 h (AUC = 0.722, sensitivity = 84.20%, specificity = 52.70%), eGFR < 60 ml/min/1.73 m (AUC = 0.718, sensitivity = 81.30%, specificity = 39.20%) and S1 lesion (AUC = 0.703, sensitivity = 75.50%, specificity = 65.10%).Children with urinary RBP ≥ 0.7µg/ml were associated with a 2.513-fold risk than patients with urinary RBP < 0.7µg/ml (P = 0.003). Our study suggested that immunosuppressive therapy may reduce the risk of progression in IgAN children had both eGFR > 50 ml/min/1.73 m and proteinuria of at least 1 g/day.
This is the first report that the 15-year renal survival rate of children with IgAN in China was 84%. At the same time, this is the first study to reveal that urinary RBP ≥ 0.7µg/ml may indicate a poor renal outcome. In addition, this study supports immunosuppressive therapy for IgAN children had both proteinuria ≥1 g/day and initial eGFR > 50 ml/min/1.73m.
大量儿童IgA肾病(IgAN)队列的长期肾脏转归尚不清楚。IgAN是一种进行性疾病,探索新的生物标志物对于预测IgAN的疾病活动和进展至关重要。此外,关于儿童何时开始免疫抑制治疗存在激烈争论。我们旨在确定中国儿童IgAN的长期肾脏存活率,找出一些未被发现的危险因素,并研究何时进行免疫抑制治疗对肾脏转归有益。
纳入1243例IgAN患儿,对其2000年至2017年肾活检后至少随访1年。评估长期肾脏存活率、未被发现的危险因素以及免疫抑制和非免疫抑制治疗的肾脏存活率。研究的主要终点是估计肾小球滤过率(eGFR)降低≥50%或终末期肾病(ESRD)或死亡的复合结局。
中位随访时间为86.8个月(四分位间距54.7 - 140.2个月)。5年、10年和15年的肾脏存活率分别为95.3%、90.3%和84%。Cox多因素回归和Kaplan-Meier分析显示,高血压、高尿酸血症、24小时尿蛋白(24h-UP)水平高、初始eGFR低、尿C3水平高、视黄醇结合蛋白(RBP)水平高、节段性肾小球硬化(S)以及肾小管萎缩和间质纤维化(T)与肾脏转归相关。对肾脏转归具有统计学显著预测效能的指标为:RBP≥0.7µg/ml(AUC = 0.899,敏感性 = 84.00%,特异性 = 86.00%)、24h-UP≥1g/24h(AUC = 0.722,敏感性 = 84.20%,特异性 = 52.70%)、eGFR < 60ml/min/1.73m²(AUC = 0.718,敏感性 = 81.30%,特异性 = 39.20%)和S1病变(AUC = 0.703,敏感性 = 75.50%,特异性 = 65.10%)。尿RBP≥0.7µg/ml的儿童比尿RBP < 0.7µg/ml的患者风险高2.513倍(P = 0.003)。我们的研究表明,免疫抑制治疗可能降低eGFR > 50ml/min/1.73m²且蛋白尿至少1g/天的IgAN儿童的疾病进展风险。
这是首篇报道中国IgAN患儿15年肾脏存活率为84%的研究。同时,这是首次揭示尿RBP≥0.7µg/ml可能提示不良肾脏转归的研究。此外,本研究支持对蛋白尿≥1g/天且初始eGFR > 50ml/min/1.73m²的IgAN儿童进行免疫抑制治疗。